DermTech Inc. (NASDAQ:DMTK) previous close was $43.22 while the outstanding shares total 27.15M. The firm has a beta of 0.84. DMTK’s shares traded higher over the last trading session, gaining 1.41% on 06/08/21. The shares fell to a low of $40.76 before closing at $43.83. Intraday shares traded counted 0.96 million, which was 26.45% higher than its 30-day average trading volume of 1.31M. The stock’s Relative Strength Index (RSI) is 59.44, with weekly volatility at 8.14% and ATR at 3.30. The DMTK stock’s 52-week price range has touched low of $9.64 and a $84.49 high.
Investors have identified the Diagnostics & Research company DermTech Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.29 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
DermTech Inc. (DMTK) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 261.73 million total, with 7.1 million as their total liabilities.
Having a look at the companyâ€™s valuation, the company is expected to record -2.77 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on DMTK sounds very interesting.
Is the stock of DMTK attractive?
In related news, Chief Executive Officer, Dobak John sold 9,530 shares of the companyâ€™s stock in a transaction that recorded on Jun 02. The sale was performed at an average price of 40.00, for a total value of 381,200. As the sale deal closes, the Chief Executive Officer, Dobak John now sold 2,970 shares of the companyâ€™s stock, valued at 119,443. Also, Director, Picozza Enrico sold 20,297 shares of the companyâ€™s stock in a deal that was recorded on May 26. The shares were price at an average price of 40.08 per share, with a total market value of 813,577. Following this completion of acquisition, the Chief Commercial Officer, Wood Todd Michael now holds 10,000 shares of the companyâ€™s stock, valued at 400,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 6.00%.
6 out of 6 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on DermTech Inc.. 0 analysts has assigned a Sell rating on the DMTK stock. The 12-month mean consensus price target for the companyâ€™s shares has been set at $62.00.